Compare Ambarella Inc (AMBA) vs Oscar Health Inc (OSCR) Price & Performance

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

OSCR trades at $30.54, down 2.12% today but up significantly year-to-date. Technicals are bullish with moving averages supporting the uptrend, while oscillators show neutral momentum. Fundamentally, revenue grew to $11.70B in 2025 with a net loss of $443M, but 2026 guidance projects improved profitability. Recent news highlights strong Q1 2026 earnings beat and reaffirmed growth targets at industry conferences.

Outlook remains optimistic due to strong revenue growth and operational improvements, but risks include persistent net losses and competitive pressures. Analyst consensus is mixed with a $22.50 price target below current levels, suggesting cautious optimism amid execution risks.